Prospective Observational Study To Identify Patients With Advanced/Metastatic Nsclc And Alk Translocation And To Establish Their Therapeutic Management (Idealk)
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IDEALK
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 10 Aug 2016 Planned number of patients changed from 1 to 100.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.